| Q26749211 | Carbohydrate-induced secretion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 |
| Q85246587 | Changes in glucose transporters, gluconeogenesis, and circadian clock after duodenal-jejunal bypass surgery |
| Q63384107 | Development of SGLT1 and SGLT2 inhibitors |
| Q37983846 | Diet: friend or foe of enteroendocrine cells--how it interacts with enteroendocrine cells |
| Q39339199 | Dietary 1-monoolein decreases postprandial GIP release by reducing jejunal transport of glucose and fatty acid in rodents. |
| Q40012754 | Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. |
| Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
| Q43142618 | Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion |
| Q57791608 | Diversity of enteroendocrine cells investigated at cellular and subcellular levels: the need for a new classification scheme |
| Q38468345 | Does nutrient sensing determine how we "see" food? |
| Q37518286 | Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations |
| Q38130748 | Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. |
| Q42721056 | Exposure to low level of arsenic and lead in drinking water from Antofagasta city induces gender differences in glucose homeostasis in rats. |
| Q49414493 | GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose |
| Q39047697 | Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. |
| Q90260620 | Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function |
| Q28660291 | Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener |
| Q38185705 | Glucose absorption in small intestinal diseases. |
| Q51158062 | Glucose elicits cephalic-phase insulin release in mice by activating KATP channels in taste cells. |
| Q84233487 | Glucose transporter/T1R3-expressing cells in rat tracheal epithelium |
| Q54372455 | Glucose transporters are expressed in taste receptor cells. |
| Q60046828 | Gut Mechanisms Linking Intestinal Sweet Sensing to Glycemic Control |
| Q43112999 | Gut glucose metabolism in rainbow trout: implications in glucose homeostasis and glucosensing capacity |
| Q51349034 | Improved glycemic control in mice lacking Sglt1 and Sglt2. |
| Q38787917 | Intestinal SGLT1 in metabolic health and disease |
| Q35858749 | Mathematical Modeling of Interacting Glucose-Sensing Mechanisms and Electrical Activity Underlying Glucagon-Like Peptide 1 Secretion |
| Q48310006 | Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine. |
| Q38589032 | Mechanisms for the cardiovascular effects of glucagon-like peptide-1. |
| Q34481610 | Metabolic effects of non-nutritive sweeteners |
| Q28072517 | Microbial regulation of GLP-1 and L-cell biology |
| Q37702790 | Molecular mechanisms underlying nutrient detection by incretin-secreting cells |
| Q35612377 | Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion |
| Q37976164 | Nerveless and gutsy: intestinal nutrient sensing from invertebrates to humans |
| Q35869027 | Non-nutritive sweeteners, energy balance, and glucose homeostasis |
| Q37969863 | Nutrient detection by incretin hormone secreting cells |
| Q37814881 | Nutrition and L and K-enteroendocrine cells |
| Q28070256 | Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review |
| Q38503042 | Oral and intestinal sweet and fat tasting: impact of receptor polymorphisms and dietary modulation for metabolic disease |
| Q38058244 | Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. |
| Q38364477 | Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon-like peptide-1 secretion |
| Q37235028 | Post-oral appetite stimulation by sugars and nonmetabolizable sugar analogs |
| Q39341291 | Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. |
| Q34979979 | Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. |
| Q35175990 | RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice |
| Q33835543 | Rapid post-oral stimulation of intake and flavor conditioning in rats by glucose but not a non-metabolizable glucose analog |
| Q26830947 | Recent advances in gut nutrient chemosensing |
| Q24564811 | Renal effects of dapagliflozin in patients with type 2 diabetes |
| Q35994290 | Role of gut nutrient sensing in stimulating appetite and conditioning food preferences |
| Q36197966 | Role of monosaccharide transport proteins in carbohydrate assimilation, distribution, metabolism, and homeostasis |
| Q39553060 | Role of sodium-glucose transporters in glucose uptake of the intestine and kidney |
| Q36902520 | SGLT1 sugar transporter/sensor is required for post-oral glucose appetition |
| Q33744641 | Selected tetrapeptides lead to a GLP-1 release from the human enteroendocrine cell line NCI-H716 |
| Q37868939 | Sensing via intestinal sweet taste pathways |
| Q38783130 | Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. |
| Q90514635 | Sodium-glucose Co-transporters: Functional Properties and Pharmaceutical Potential |
| Q49218653 | Spatiotemporal Modeling of Triggering and Amplifying Pathways in GLP-1 Secreting Intestinal L Cells |
| Q26765259 | Stimulation of incretin secreting cells |
| Q38562860 | Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity |
| Q35682171 | Taste and move: glucose and peptide transporters in the gastrointestinal tract |
| Q26799942 | The L-Cell in Nutritional Sensing and the Regulation of Appetite |
| Q36750486 | The effect of peanut and grain bar preloads on postmeal satiety, glycemia, and weight loss in healthy individuals: an acute and a chronic randomized intervention trial |
| Q93164066 | The gut-brain axis mediates sugar preference |
| Q91304787 | The metabolic role of vagal afferent innervation |
| Q27319522 | The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing |
| Q34263449 | The role of sweet taste in satiation and satiety. |
| Q40626757 | The structure of wheat bread influences the postprandial metabolic response in healthy men. |
| Q37779101 | Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? |
| Q36178550 | Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance |
| Q36175901 | Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery |
| Q26783350 | Treatment of prediabetes |
| Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
| Q91970207 | What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition |